Strong objective responses rates were seen in the phase I/II LIBRETTO trial, which studied RET inhibition with selpercatinib in patients with RET-mutant medullary thyroid cancer and for those with other RET fusion-positive thyroid cancer. The registrational findings were recently presented at ESMO Congress 2019.